Abstracts tagged "interferons and nephritis"

Abstract Number: 2130 • 2018 ACR/ARHP Annual Meeting
Interferon Induced Gene Transcripts Are Differentially Upregulated in the Kidney of Lupus Nephritis Patients Irrespective of Activity or Damage
S. Sam Lim¹, Alton B Farris¹, Tobias Guennel², Shiliang Wang³, Jason Cobb¹, Dominic Sinibaldi⁴, Scott Jenks¹, Ignacio Sanz¹, Xiang Guo³, Gabor Illei⁵, Kui Shen², Monica Battle¹, Chungwen Wei¹ and WI White³, ¹Emory University School of Medicine, Atlanta, GA, ²Precision for Medicine, Frederick, MD, ³MedImmune, Gaithersburg, MD, ⁴MedImmune, Gaithersberg, MD, ⁵Viela Bio, Gaithersburg, USA, Gaithersberg, MD
Background/Purpose: Lupus nephritis (LN) afflicts 12-69% lupus patients. Even with the best available therapies, complete response is achieved in only 10-85% of patients. The risk…
Abstract Number: 541 • 2013 ACR/ARHP Annual Meeting
An Essential Role For Caspase-1 In The Induction Of Murine Lupus and Its Associated Vascular Damage
J. Michelle Kahlenberg¹, Srilakshmi Yalavarthi², Wenpu Zhao², Jeffrey Hodgin³, Tamra J. Reed⁴, Noriko M. Tsuji⁵ and Mariana J. Kaplan⁶, ¹Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan Rheumatology, Ann Arbor, MI, ³Department of Pathology, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ⁵3Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan, ⁶Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune syndrome associated with organ damage and an elevated risk of cardiovascular disease (CVD) resulting from activation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].